HLL is reliable hand in Medical Health Services: JP Nadda
- byDoctor News Daily Team
- 27 October, 2025
- 0 Comments
- 0 Mins
New Delhi:HLL Lifecare Limited, a Mini-Ratna Central Public Sector Enterprise (CPSE) under the Ministry of Health & Family Welfare, Government of India, has reinforced its strong financial performance by paying a record dividend of Rs. 69.53 crore to the Government of India for the financial year 2024–25. This is among the highest dividends ever paid by the company. The dividend cheque was presented to Shri J.P. Nadda, Hon’ble Union Minister of Health & Family Welfare, by Dr. Anitha Thampi, Chairperson, HLL, in the presence of Smt. Anupriya Patel, Minister of State for Health & Family Welfare; Smt. Punya Salila Srivastava, Union Health Secretary; Shri Hovyeda Abbas, AS&FA; and Shri Vijay Nehra, Joint Secretary, Ministry of Health & Family Welfare. Senior officials from HLL, including Shri N. Ajit, Director (Marketing), and Shri Ramesh P, Director (Finance), were also present. Speaking at the occasion, Shri J.P. Nadda asserted that, HLL is a reliable name in the field of Medical Services and is committed towards the national vision of accessible, affordable and quality healthcare to all. Commending HLL’s performance, Shri J.P. Nadda, stated that, HLL along with its subsidiaries and Amrit pharmacies have emerged as a key player in transforming the health sector. He highlighted that in the last 10 years, over 6.7 crore people have benefited through the affordable medicines of the Amrit Pharmacies, thereby saving more than Rs. 8000 Crores in terms of their out-of-pocket expenditure. The financial year 2024–25 witnessed comprehensive growth across both HLL’s manufacturing and service portfolios. Revenue from operations increased to Rs. 4,500 crore, reflecting a 20% growth over the previous year. The company’s net worth rose significantly to Rs. 1,100 crore as on March 31, 2025. On a consolidated basis, including its subsidiaries — HITES, GAPL, and Lifespring Hospitals — the HLL Group recorded a total revenue of Rs. 4,900 crore, marking a 19% growth over the previous fiscal.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Common cholesterol-lowering drugs may reduce risk...
- 27 October, 2025
Colchicine Fails to Improve Outcomes in Long COVID...
- 27 October, 2025
Study uncovers link between brain activity, energy...
- 27 October, 2025
Early-Life Sugar Restriction Linked to Lower Adult...
- 27 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!